Brief: Mabion Gets Permission To Run Bridging Clinical Trial Of MabionCD20 Drug in Georgia
14/10/2021 11:22
Oct 14 (Reuters) - Mabion SA MABP.WA :
* GETS PERMISSION FROM GEORGIA'S HEAD OF MEDICINES AUTHORITY
TO
RUN BRIDGING CLINICAL TRIAL OF MABIONCD20 DRUG FOR RHEUMATOID
ARTHRITIS PATIENTS
Source text for Eikon: ID:nEM5lb5Qxa
Further company coverage: MABP.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects